Human Genome Sciences ($HGSI) has been steadily ramping up its manufacturing ops for Benlysta this year. And now that it's breezed past its expert panel review with a big vote in the lupus drug's favor, HGS says that it's working around the clock to produce more in anticipation of an approval. The FDA has a December 9 deadline for making a decision on the drug, but nothing is guaranteed and some analysts have speculated that questions about labeling could force the agency to take more time before it offers a green light on HGS's first market launch. Report